Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Revenue (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Revenue data on record, last reported at $132000.0 in Q4 2025.

  • For Q4 2025, Revenue rose 83.33% year-over-year to $132000.0; the TTM value through Dec 2025 reached $70.8 million, up 23359.93%, while the annual FY2025 figure was $70.8 million, 23359.93% up from the prior year.
  • Revenue reached $132000.0 in Q4 2025 per VRDN's latest filing, down from $70.6 million in the prior quarter.
  • Across five years, Revenue topped out at $70.6 million in Q3 2025 and bottomed at $72000.0 in Q2 2023.
  • Average Revenue over 5 years is $3.8 million, with a median of $101500.0 recorded in 2022.
  • Peak YoY movement for Revenue: plummeted 93.97% in 2023, then soared 81958.14% in 2025.
  • A 5-year view of Revenue shows it stood at $214000.0 in 2021, then tumbled by 50.93% to $105000.0 in 2022, then crashed by 31.43% to $72000.0 in 2023, then changed by 0.0% to $72000.0 in 2024, then soared by 83.33% to $132000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $132000.0 in Q4 2025, $70.6 million in Q3 2025, and $75000.0 in Q2 2025.